(Q44872669)

7 December 2017

title

Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients (English)

1 reference

7 December 2017

0 references

1 reference

4

Birte Y Glenthøj

1 reference

7 December 2017

1

Birgitte Fagerlund

1 reference

7 December 2017

Torben Mackeprang

2

1 reference

7 December 2017

Anders Gade

series ordinal

3

1 reference

7 December 2017

publication date

1 May 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

9

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

364-374

1 reference

Effects of risperidone on information processing and attention in first-episode schizophrenia

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Cognition, schizophrenia, and the atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

RBANS has reasonable test-retest reliability in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Reliability of the WAIS-R with psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Stability and course of neuropsychological deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Children's production on verbal and non-verbal fluency tasks

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Relationships between medication treatments and neuropsychological test performance in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Atypical antipsychotic drugs improve cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Another view of therapy for cognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Does cognitive function improve with quetiapine in comparison to haloperidol?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Wisconsin card sorting test and work performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Diagnostic stability of first-episode psychosis. Comparison of ICD-10 and DSM-III-R systems

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Intact implicit learning in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Should schizophrenia be treated as a neurocognitive disorder?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Cognitive improvement in schizophrenia with novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

The functional significance of symptomatology and cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900009354

7 January 2021

10.1017/S1092852900009354

Identifiers

DOI

0 references

1 reference